Abstract:Introduction Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease with limited therapeutic options and high lethality, related to alveolar type II epithelial (ATII) cell dysregulation, the abnormal repair of alveolar epithelial cells and activation of fibroblasts promote the development of pulmonary fibrosis. Fatty acid binding protein 1 (FABP1) was significantly downregulated in the fibrotic state by proteomics screening in our previous date, and the ATII cell dysregulation can be mediated by FABP1 via regulating fatty acid metabolism and intracellular transport. The aim of this study was to evaluate the role and potential mechanism of FABP1 in the development of pulmonary fibrosis. Methods Proteomics screening was used to detect changes of the protein profiles in two different types (induced by bleomycin and silica, respectively) of pulmonary fibrosis models. The localisation of FABP1 in mouse lung was detected by Immunofluorescence and immunohistochemistry. Experimental methods such as lung pathology, micro-CT, western blotting, small animal imaging in vivo, EdU, etc were used to verify the role of FABP1 in pulmonary fibrosis. Results The expression of FABP1 in the mouse lung was significantly reduced in the model of pulmonary fibrosis from our proteomic analysis and immunological methods, the double immunofluorescence staining showed that FABP1 was mainly localised in type II alveolar epithelial cells. Additionally, the expression of FABP1 was negatively correlated with the progression of pulmonary fibrosis. Further in vivo and in vitro experiments showed that overexpression of FABP1 alleviated pulmonary fibrosis by protecting alveolar epithelium from injury and promoting cell survival. Conclusion Our findings provide a proof-of-principle that FABP1 may represent an effective treatment for pulmonary fibrosis by regulating alveolar epithelial regeneration, which may be associated with the fatty acid metabolism in ATII cells.

Research advances of fatty acid-binding proteins in pain regulation

FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain

Adipocytokines: Emerging therapeutic targets for pain management

The Biological Functions and Regulatory Mechanisms of Fatty Acid Binding Protein 5 in Various Diseases

Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management

The related mechanism of complete Freund's adjuvant-induced chronic inflammation pain based on metabolomics analysis

Analysis of binding affinity and docking of novel fatty acid-binding protein (FABP) ligands

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Fatty Acid-Binding Proteins Aggravate Cerebral Ischemia-Reperfusion Injury in Mice.

Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors

A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain

Small molecule inhibitors of human adipocyte fatty acid binding protein (FABP4).

Anti-Inflammatory Effects of BoNT/A Against Complete Freund’s Adjuvant-Induced Arthritis Pain in Rats: Transcriptome Analysis

Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination.

[TRPV1: an Important Molecule Involved in the Peripheral Sensitization During Chronic Pain and Central Pain Modulation].

Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases

Neuropeptide FF and Its Receptors: Therapeutic Applications and Ligand Development

In silico identification of A1 agonists and A2a inhibitors in pain based on molecular docking strategies and dynamics simulations

Therapeutic effects of fatty acid binding protein 1 in mice with pulmonary fibrosis by regulating alveolar epithelial regeneration

Wnt signaling: A prospective therapeutic target for chronic pain

Farnesyl pyrophosphate is a novel pain-producing molecule via specific activation of TRPV3